KRAS and neoplasm: Indeed with a stated conversion factor of 44 million KRAS-mutant cells for every mutant KRAS template/ml [17], the estimated MT-KRAS tumor burden ranged from 0.13 grams to 21 grams, with 7/9 patients with circulating MT-KRAS having <5 grams of tumor harboring a KRAS mutation.